LT3932932T - Neuroaktyvūs steroidai ir jų naudojimo būdai - Google Patents

Neuroaktyvūs steroidai ir jų naudojimo būdai

Info

Publication number
LT3932932T
LT3932932T LTEP21172859.7T LT21172859T LT3932932T LT 3932932 T LT3932932 T LT 3932932T LT 21172859 T LT21172859 T LT 21172859T LT 3932932 T LT3932932 T LT 3932932T
Authority
LT
Lithuania
Prior art keywords
neuroactive steroids
neuroactive
steroids
Prior art date
Application number
LTEP21172859.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Gabriel Martinez Botella
Boyd Harrison
Albert J. Robichaud
Francesco G. Salituro
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Publication of LT3932932T publication Critical patent/LT3932932T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP21172859.7T 2013-03-13 2014-03-13 Neuroaktyvūs steroidai ir jų naudojimo būdai LT3932932T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779735P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
LT3932932T true LT3932932T (lt) 2025-09-10

Family

ID=51625437

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP21172859.7T LT3932932T (lt) 2013-03-13 2014-03-13 Neuroaktyvūs steroidai ir jų naudojimo būdai
LTEP14774060.9T LT2968369T (lt) 2013-03-13 2014-03-13 Neuroaktyvūs steroidai ir jų panaudojimo būdai
LTEP18190034.1T LT3461834T (lt) 2013-03-13 2014-03-13 Neuroaktyvūs steroidai

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP14774060.9T LT2968369T (lt) 2013-03-13 2014-03-13 Neuroaktyvūs steroidai ir jų panaudojimo būdai
LTEP18190034.1T LT3461834T (lt) 2013-03-13 2014-03-13 Neuroaktyvūs steroidai

Country Status (25)

Country Link
US (6) US20160031930A1 (enExample)
EP (4) EP2968369B1 (enExample)
JP (6) JP6255082B2 (enExample)
CN (3) CN118702755A (enExample)
AU (5) AU2014243773B2 (enExample)
BR (1) BR112015022174B1 (enExample)
CA (2) CA3114062A1 (enExample)
CY (2) CY1120934T1 (enExample)
DK (3) DK3932932T3 (enExample)
ES (3) ES2699445T3 (enExample)
FI (1) FI3932932T3 (enExample)
HR (3) HRP20181994T1 (enExample)
HU (2) HUE055668T2 (enExample)
IL (3) IL280068B2 (enExample)
LT (3) LT3932932T (enExample)
MX (2) MX388210B (enExample)
PL (3) PL3932932T3 (enExample)
PT (3) PT2968369T (enExample)
RS (3) RS67266B1 (enExample)
RU (1) RU2684103C2 (enExample)
SI (3) SI3932932T1 (enExample)
SM (3) SMT202500336T1 (enExample)
TR (1) TR201817995T4 (enExample)
WO (1) WO2014160480A1 (enExample)
ZA (1) ZA201506729B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
US9515617B2 (en) 2010-10-27 2016-12-06 Merus Audio Aps Audio amplifier using multi-level pulse width modulation
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
US20170304321A1 (en) 2014-10-07 2017-10-26 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
SMT202100476T1 (it) * 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
JP6882996B2 (ja) * 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
BR112018000129B1 (pt) * 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
SI3436022T1 (sl) * 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) * 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CN110267966B (zh) * 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP4105223B1 (en) * 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN106632565A (zh) * 2016-11-07 2017-05-10 湖南科瑞生物制药股份有限公司 一种合成胆固醇的新方法
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
IL293525A (en) 2019-12-06 2022-08-01 Marinus Pharmaceuticals Inc Ganaxolone for use in the treatment of multiple sclerosis complex
US20240252514A1 (en) * 2021-05-04 2024-08-01 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease
KR20240035444A (ko) 2021-06-11 2024-03-15 세이지 테라퓨틱스, 인크. 알츠하이머병 치료를 위한 신경활성 스테로이드
JP2024532273A (ja) * 2021-08-25 2024-09-05 セージ セラピューティクス， インコーポレイテッド ポジティブｎｍｄａモジュレート化合物及びその使用方法
US20240417423A1 (en) * 2021-09-22 2024-12-19 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) * 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CA3242623A1 (en) * 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of huntington's disease
CN114478672B (zh) * 2022-01-27 2024-06-14 浙江仙居君业药业有限公司 一种he3286的合成方法
IL317904A (en) 2022-06-24 2025-02-01 Sage Therapeutics Inc Crystalline forms of neuroactive steroid
CA3261849A1 (en) 2022-07-12 2024-01-18 Sage Therapeutics Inc CRYSTALLINE FORM OF A NEUROACTIVE STEROID
WO2024229290A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of use thereof
WO2025227053A1 (en) * 2024-04-25 2025-10-30 Sage Therapeutics, Inc. Nmda receptor positive allosteric modulatory compositions and methods of use thereof

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2259698A (en) 1938-05-07 1941-10-21 Rare Chemicals Inc Physiologically effective substance and process of preparing same
US2594323A (en) 1948-07-22 1952-04-29 Upjohn Co 24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) 1950-06-07 1954-03-23 Schering Corp 25-ethinyl steroids
US3079385A (en) 1961-01-24 1963-02-26 Roussel Uclaf Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
JPS5324071B2 (enExample) 1974-04-30 1978-07-18
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) 1975-10-10 1982-03-31 Hoffmann La Roche Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) 1976-12-28 1983-09-08 帝人株式会社 ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
JPS54163565A (en) 1978-06-09 1979-12-26 Teijin Ltd 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) 1978-08-01 1979-11-13 Kaiser Emil T Synthesis of steroids
US4269777A (en) 1979-05-21 1981-05-26 Wisconsin Alumni Research Foundation Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) 1980-08-13 1982-02-26 Teijin Ltd 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
ATE45347T1 (de) 1985-05-30 1989-08-15 Taisho Pharmaceutical Co Ltd Vitamin d3-derivate.
JPS62187485A (ja) 1986-02-13 1987-08-15 Teijin Ltd ２４，２５−エポキシコレステロ−ル類の製造法
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
DE4338316A1 (de) 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5595996A (en) 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GEP20002033B (en) 1994-11-23 2000-04-10 Cocensys Inc Us Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor
JPH08268917A (ja) 1995-03-31 1996-10-15 D D S Kenkyusho:Kk 癌組織への移行性の高い制癌剤
CA2223996A1 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US5792635A (en) 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
JPH11507929A (ja) 1995-06-23 1999-07-13 ノボ ノルディスク アクティーゼルスカブ 減数分裂調節化合物
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
EP0840612A1 (en) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1997042215A1 (en) 1996-05-06 1997-11-13 Bionumerik Pharmaceuticals, Inc. Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) 1996-06-10 1997-12-22 Teijin Ltd ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en) 1997-07-22 2000-09-19 Atwell; Ronald C. Apparatus for protecting coin-operated telephones from vandalism and larceny
JP2002514621A (ja) 1998-05-11 2002-05-21 ノボ ノルディスク アクティーゼルスカブ 置換グアニジン及びジアミノニトロエテン、それらの製造及び使用
IL139241A0 (en) 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
CA2331962A1 (en) 1998-05-13 1999-11-18 Novo Nordisk A/S Meiosis regulating compounds
US8541600B2 (en) 1998-11-24 2013-09-24 Harbor Therapeutics, Inc. 11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de) 1999-04-15 2000-10-19 Schering Ag Ent-Steroide als selektiv wirksame Estrogene
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
CN1111167C (zh) 1999-10-22 2003-06-11 中国科学院上海有机化学研究所 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh) 1999-11-12 2003-01-08 中国科学院上海有机化学研究所 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0019290D0 (en) 2000-08-04 2000-09-27 Symphar Sa Methods for inducing apolipoprotein E secretion
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
WO2003039480A2 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
US20030162758A1 (en) 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
KR101130212B1 (ko) 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
WO2003082893A2 (en) 2002-03-27 2003-10-09 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US20050142192A1 (en) 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en) 2004-02-21 2004-03-24 Univ Edinburgh Uses of er-beta modulators
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
DE602005025391D1 (de) 2004-11-01 2011-01-27 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
WO2007098281A2 (en) 2006-02-27 2007-08-30 Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
CN101164540A (zh) * 2006-08-03 2008-04-23 中山大学 海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
ES2662500T3 (es) 2006-11-21 2018-04-06 Asarina Pharma Ab El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central
AU2008331808B2 (en) 2007-03-16 2014-08-21 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
KR101767849B1 (ko) 2007-06-20 2017-08-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059239A2 (en) 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
US20110118353A1 (en) 2007-11-06 2011-05-19 N. V. Organon Method of hormone suppression in humans
WO2009090063A1 (en) 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
US8273737B2 (en) 2008-01-25 2012-09-25 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
TWI478709B (zh) 2008-02-19 2015-04-01 Earnest Medicine Co Ltd A useful oral or enteral composition for the recovery of bodily functions
CA2722776A1 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
WO2011028794A2 (en) 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr) 2009-12-02 2015-10-16 Assist Publ Hopitaux Marseille Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN102939011A (zh) * 2010-03-03 2013-02-20 萨托里医药公司 用于治疗神经变性病症的化合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en) 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
US8969525B2 (en) 2010-11-09 2015-03-03 Enzo Life Sciences, Inc. Hydroxycholesterol immunoassay
US20150031655A1 (en) 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
CA2843436A1 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6117191B2 (ja) 2011-10-07 2017-04-19 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
EP2841067A4 (en) 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
US20140149272A1 (en) 2012-08-17 2014-05-29 Trueex Group Llc Interoffice bank offered rate financial product and implementation
SG10201706063UA (en) 2012-12-18 2017-09-28 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2016505038A (ja) 2013-01-23 2016-02-18 スファエラ ファーマ プライベート リミテッド ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物
AU2014212487C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
RU2021111681A (ru) 2013-03-13 2021-05-11 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применение
RS67266B1 (sr) * 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
EP3900738A1 (en) 2014-02-08 2021-10-27 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016007762A1 (en) 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
US20170304321A1 (en) 2014-10-07 2017-10-26 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
SMT202100476T1 (it) 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
GB2557875A (en) 2015-09-02 2018-07-04 Univ Swansea Diagnostic methods and kits
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
BR112019027458A2 (pt) 2017-06-23 2020-07-07 Intercept Pharmaceuticals, Inc. métodos e intermediários para a preparação de derivados de ácidos biliares
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders

Also Published As

Publication number Publication date
PT3932932T (pt) 2025-09-29
JP2021152086A (ja) 2021-09-30
EP2968369B1 (en) 2018-08-29
TR201817995T4 (en) 2019-02-21
EP3461834A1 (en) 2019-04-03
BR112015022174A8 (pt) 2019-11-26
JP2019135261A (ja) 2019-08-15
WO2014160480A8 (en) 2015-01-08
US20170305960A1 (en) 2017-10-26
CY1124629T1 (el) 2022-07-22
NZ712141A (en) 2020-10-30
SMT202500336T1 (it) 2025-11-10
RS67266B1 (sr) 2025-10-31
EP2968369A1 (en) 2016-01-20
AU2021200205B2 (en) 2022-09-01
IL280068B2 (en) 2025-06-01
JP2016513663A (ja) 2016-05-16
RS58166B1 (sr) 2019-03-29
AU2022279366A1 (en) 2023-01-19
BR112015022174A2 (pt) 2017-07-18
AU2025203021A1 (en) 2025-05-22
DK2968369T3 (en) 2018-12-17
AU2019201275A1 (en) 2019-03-14
RU2019109033A (ru) 2019-05-21
US10227375B2 (en) 2019-03-12
SI3461834T1 (sl) 2021-11-30
RU2684103C2 (ru) 2019-04-04
ES2699445T3 (es) 2019-02-11
JP2018030890A (ja) 2018-03-01
JP7317898B2 (ja) 2023-07-31
EP3461834B1 (en) 2021-05-19
HUE072324T2 (hu) 2025-11-28
CA2905359C (en) 2021-05-25
AU2022279366B2 (en) 2025-02-06
SMT202100475T1 (it) 2021-09-14
HRP20181994T1 (hr) 2019-03-08
PL3461834T3 (pl) 2021-12-27
PT3461834T (pt) 2021-09-10
CN105246486B (zh) 2020-11-03
PT2968369T (pt) 2018-12-05
US20240287125A1 (en) 2024-08-29
SI2968369T1 (sl) 2019-01-31
NZ751196A (en) 2020-10-30
CN112375115A (zh) 2021-02-19
SMT201800657T1 (it) 2019-01-11
ZA201506729B (en) 2017-09-27
AU2021200205A1 (en) 2021-03-18
US20190127414A1 (en) 2019-05-02
JP2022180606A (ja) 2022-12-06
IL280068B1 (en) 2025-02-01
CN118702755A (zh) 2024-09-27
DK3932932T3 (da) 2025-08-18
EP4643945A8 (en) 2025-12-17
EP2968369A4 (en) 2016-09-14
LT2968369T (lt) 2018-12-27
JP7715692B2 (ja) 2025-07-30
HK1220375A1 (en) 2017-05-05
AU2019201275B2 (en) 2020-10-15
CN105246486A (zh) 2016-01-13
JP6255082B2 (ja) 2017-12-27
MX362544B (es) 2019-01-24
US20220064207A1 (en) 2022-03-03
CY1120934T1 (el) 2019-12-11
US11905309B2 (en) 2024-02-20
EP3932932B8 (en) 2025-11-19
EP4643945A2 (en) 2025-11-05
ES2886506T3 (es) 2021-12-20
US11104701B2 (en) 2021-08-31
ES3042115T3 (en) 2025-11-18
IL280068A (en) 2021-03-01
DK3461834T3 (da) 2021-08-23
IL241301A0 (en) 2015-11-30
PL3932932T3 (pl) 2025-11-24
PL2968369T3 (pl) 2019-03-29
LT3461834T (lt) 2021-10-25
EP3932932B1 (en) 2025-07-16
HUE055668T2 (hu) 2021-12-28
RU2015143466A (ru) 2017-04-18
IL318314A (en) 2025-03-01
WO2014160480A1 (en) 2014-10-02
AU2014243773A1 (en) 2015-10-01
JP6530804B2 (ja) 2019-06-12
JP2025120299A (ja) 2025-08-15
IL241301B (en) 2021-01-31
FI3932932T3 (fi) 2025-10-15
US20160031930A1 (en) 2016-02-04
MX2015012430A (es) 2016-02-03
MX388210B (es) 2025-03-19
CA3114062A1 (en) 2014-10-02
HRP20251221T1 (hr) 2025-12-05
BR112015022174B1 (pt) 2022-07-05
SI3932932T1 (sl) 2025-10-30
HRP20211300T1 (hr) 2021-11-12
EP3932932A1 (en) 2022-01-05
US20180237470A1 (en) 2018-08-23
RS62235B1 (sr) 2021-09-30
AU2014243773B2 (en) 2018-12-13
CA2905359A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
IL286970A (en) Neuroactive steroids and methods of use thereof
LT3932932T (lt) Neuroaktyvūs steroidai ir jų naudojimo būdai
LT3488852T (lt) Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas
LT3021852T (lt) Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
LT3705488T (lt) Neuroaktyvūs steroidai, kompozicijos ir jų naudojimas
LT2976117T (lt) Purkštuvas ir surinkimo būdas
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
FI20135956L (fi) Kiinnitin
LT3003039T (lt) Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
LT3071597T (lt) Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
EP3090813C0 (de) Paneel
DK3083173T3 (da) Panel
LT3060660T (lt) Rekombinantiniai glikoproteinai ir jų naudojimas
FI10012U1 (fi) Paneelirakenne
FI10570U1 (fi) Paneelirakenne
UA24768S (uk) Опалювальна панель
BR302013004190S1 (pt) Configuração aplicada em painel